Literature DB >> 8154963

K-ras-2 topographic genotyping of pancreatic adenocarcinoma.

S D Finkelstein1, R Przygodzki, V E Pricolo, R Sayegh, A Bakker, P A Swalsky, G Keller.   

Abstract

OBJECTIVE: To determine the frequency distribution of K-ras-2 point mutation genotypes in pancreatic adenocarcinoma and to evaluate the effectiveness of K-ras-2 genotyping as a means to predict localized disease and potential long-term survival.
DESIGN: Topographic genotyping from archival formalin-fixed, paraffin-embedded large- and biopsy-sized tissue specimens as well as cytologic fluid using polymerase chain reaction products and direct sequencing together with clinicopathologic and statistical analysis.
SETTING: Tertiary care medical center with molecular diagnostics pathology laboratory. PATIENTS: Patients treated between 1988 and 1993 at Rhode Island Hospital, Providence, yielding 55 primary and 56 metastatic specimens of pancreatic adenocarcinoma.
RESULTS: Each primary pancreatic adenocarcinoma was found to contain one of eight specific genotypes that was maintained in all metastatic deposits of that individual tumor. Primary adenocarcinomas confined to the pancreatic bed at diagnosis were predominantly of a normal genotype (56% [14/25]). Pancreatic adenocarcinomas progressing to distant hematogenous metastasis were almost exclusively mutated (88% [7/8]; P < .005). Patients undergoing pancreatic resection (Whipple's operation) and having a normal K-ras-2-genotype (58% [11/19]) had a significantly longer survival (21.3 months) than similar patients with mutated tumors (8.2 months).
CONCLUSIONS: The findings support the feasibility of K-ras-2 topographic genotyping to identify potentially indolent disease and suggest a potentially useful role in the preoperative evaluation of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154963     DOI: 10.1001/archsurg.1994.01420280037005

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  6 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  Representativeness of microorgans from human colorectal tumors.

Authors:  S D Finkelstein; R Sayegh; P A Swalsky; A Bakker; R Guzman; B Rotman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

3.  Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique.

Authors:  D B Evans; M L Frazier; C Charnsangavej; R L Katz; L Larry; J L Abbruzzese
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

Review 4.  Molecular biology of exocrine pancreatic cancer.

Authors:  J L Soto; V M Barbera; M Saceda; A Carrato
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

Review 5.  K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.

Authors:  Tao Li; Yuanting Zheng; Hong Sun; Rongyuan Zhuang; Jing Liu; Tianshu Liu; Weimin Cai
Journal:  Med Oncol       Date:  2016-05-25       Impact factor: 3.064

6.  Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features.

Authors:  Jie Peng; Ali Kord Valeshabad; Qingfu Li; Yuan Wang
Journal:  Oncol Lett       Date:  2012-12-17       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.